<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="*Correspondence: Samit Chattopadhyay samitc@goa.bits-pilani.ac.in; samitchatterji@yahoo.com This article was submitted to" exact="Viral" post="Immunology, a section of the journal Frontiers in Immunology"/>
 <result pre="science has made it possible to identify that the novel" exact="infectious" post="agent is from the coronavirus family. Rapid genome sequencing"/>
 <result pre="in diverse populations, and potential preventive measures. Coronavirus attacks the" exact="respiratory" post="system, causing pneumonia and lymphopenia in infected individuals. Viral"/>
 <result pre="and potential preventive measures. Coronavirus attacks the respiratory system, causing" exact="pneumonia" post="and lymphopenia in infected individuals. Viral components like spike"/>
 <result pre="preventive measures. Coronavirus attacks the respiratory system, causing pneumonia and" exact="lymphopenia" post="in infected individuals. Viral components like spike and nucleocapsid"/>
 <result pre="the respiratory system, causing pneumonia and lymphopenia in infected individuals." exact="Viral" post="components like spike and nucleocapsid proteins trigger an immune"/>
 <result pre="immune response in the host to eliminate the virus. These" exact="viral" post="antigens can be either recognized by the B cells"/>
 <result pre="antibody production, increased cytokine secretion, and cytolytic activity in the" exact="acute" post="phase of infection. Genetic polymorphism in MHC enables it"/>
 <result pre="MHC alleles and its downregulated expression has been correlated with" exact="disease" post="severity against influenza and coronaviruses. Studies have reported that"/>
 <result pre="and develops an exhaustive T-cell pool at higher loads of" exact="viral infection." post="As there are no specific treatments available for this"/>
 <result pre="treatment of diseases like SARS, MERS, HIV, ebola, malaria, and" exact="tuberculosis" post="are being given to COVID-19 patients, and clinical trials"/>
 <result pre="against virus particles along with immuno-modulation of cytokines like IL-6," exact="Type I" post="interferons (IFNs), and TNF-Î± that could help in combating"/>
 <result pre="in late December 2019 as merely a few cases of" exact="pneumonia" post="in Wuhan, China. The patients were exhibiting common symptoms"/>
 <result pre="the onset of winter, similar to that of the previous" exact="Severe" post="Acute Respiratory Syndrome (SARS) infection, the scientists first screened"/>
 <result pre="onset of winter, similar to that of the previous Severe" exact="Acute" post="Respiratory Syndrome (SARS) infection, the scientists first screened the"/>
 <result pre="of winter, similar to that of the previous Severe Acute" exact="Respiratory" post="Syndrome (SARS) infection, the scientists first screened the samples"/>
 <result pre="winter, similar to that of the previous Severe Acute Respiratory" exact="Syndrome" post="(SARS) infection, the scientists first screened the samples using"/>
 <result pre="led to the identification of the causative agent of this" exact="respiratory" post="disease, a novel coronavirus (2019-nCoV) (1). As more cases"/>
 <result pre="2020, the World Health Organization assigned a name, COrona VIrus" exact="Disease" post="2019 or COVID-19, to the disease and declared it"/>
 <result pre="a name, COrona VIrus Disease 2019 or COVID-19, to the" exact="disease" post="and declared it a pandemic on March 11, 2020."/>
 <result pre="basis of its genetic similarity to a previously known coronavirus," exact="Severe" post="Acute Respiratory Syndrome Coronavirus (SARS-CoV) (2). Transmission of SARS-CoV-2"/>
 <result pre="of its genetic similarity to a previously known coronavirus, Severe" exact="Acute" post="Respiratory Syndrome Coronavirus (SARS-CoV) (2). Transmission of SARS-CoV-2 occurs"/>
 <result pre="its genetic similarity to a previously known coronavirus, Severe Acute" exact="Respiratory" post="Syndrome Coronavirus (SARS-CoV) (2). Transmission of SARS-CoV-2 occurs when"/>
 <result pre="genetic similarity to a previously known coronavirus, Severe Acute Respiratory" exact="Syndrome" post="Coronavirus (SARS-CoV) (2). Transmission of SARS-CoV-2 occurs when a"/>
 <result pre="when a healthy individual inhales or comes into contact with" exact="respiratory" post="droplets from an infected person. The average incubation period"/>
 <result pre="an infected person. The average incubation period before patients exhibit" exact="disease" post="symptoms ranges from 2 to 14 days (3). Before"/>
 <result pre="emerged as an epidemic in 2003, followed by Middle East" exact="respiratory" post="syndrome (MERS) in 2012, both caused by a novel"/>
 <result pre="as an epidemic in 2003, followed by Middle East respiratory" exact="syndrome" post="(MERS) in 2012, both caused by a novel coronavirus"/>
 <result pre="spread, where it took months to identify the cause of" exact="infection" post="and perform genome sequencing (7), advancement in science and"/>
 <result pre="outbreak, different laboratories across the world had sequenced the whole" exact="viral" post="genome and had also provided structural and functional insights"/>
 <result pre="be a bat, which then transmitted it to some unknown" exact="intermediate" post="host that acted as a source for the transmission"/>
 <result pre="frames (ORFs) in number. At the 5â€² end of the" exact="viral" post="genome, overlapping ORFs 1a and 1b are present that"/>
 <result pre="NSP2 &amp;amp; NSP3 are also believed to impart the enhanced" exact="infection" post="abilities of the novel coronavirus (16, 17). RNA viruses"/>
 <result pre="across the globe, eight repetitive novel point mutations were observed." exact="Viral" post="genetic sequences accessed from Europe exhibited five mutation hotspots,"/>
 <result pre="sequences from North America. These unique mutations suggest that the" exact="viral" post="strains are continuously evolving across the globe and that"/>
 <result pre="the whole time (19). Another similar report analyzed 7,666 global" exact="viral" post="genomic sequences and found 198 unique mutation sites on"/>
 <result pre="structural and accessory proteins that help in assembly of the" exact="viral" post="particle and evading immune response. Interestingly, SARS-CoV-2, similar to"/>
 <result pre="polyproteins into 16 non-structural proteins (NSP1-16), which eventually create the" exact="viral" post="RNA polymerase and other accessory proteins for virus assembly"/>
 <result pre="cells and are also released into the surrounding environment via" exact="respiratory" post="droplets that are highly contagious and hence potentially spread"/>
 <result pre="droplets that are highly contagious and hence potentially spread the" exact="disease" post="to healthy individuals. Pathogenesis of COVID-19 The path followed"/>
 <result pre="naso-oral cavity. Once the virus is inhaled, it enters the" exact="epithelial" post="cells of the nasal cavity by engagement of ACE2"/>
 <result pre="the nasal cavity by engagement of ACE2 receptor with the" exact="viral" post="RBD and initiates its replication (27, 39, 40). This"/>
 <result pre="about 1â€&quot;2 days, during which the virus multiplies in the" exact="upper" post="respiratory tract, where no major hindrance is caused by"/>
 <result pre="1â€&quot;2 days, during which the virus multiplies in the upper" exact="respiratory" post="tract, where no major hindrance is caused by the"/>
 <result pre="spread (41). Soon, the virus begins to move toward the" exact="lower" post="respiratory tract via airways, and this triggers a strong"/>
 <result pre="(41). Soon, the virus begins to move toward the lower" exact="respiratory" post="tract via airways, and this triggers a strong innate"/>
 <result pre="this stage start exhibiting enhanced pro-inflammatory response that leads to" exact="viral" post="sepsis accompanied by other complications, including pulmonary edema, Acute"/>
 <result pre="that leads to viral sepsis accompanied by other complications, including" exact="pulmonary" post="edema, Acute Respiratory Distress Syndrome (ARDS), different organ failures,"/>
 <result pre="to viral sepsis accompanied by other complications, including pulmonary edema," exact="Acute" post="Respiratory Distress Syndrome (ARDS), different organ failures, and death"/>
 <result pre="viral sepsis accompanied by other complications, including pulmonary edema, Acute" exact="Respiratory" post="Distress Syndrome (ARDS), different organ failures, and death in"/>
 <result pre="accompanied by other complications, including pulmonary edema, Acute Respiratory Distress" exact="Syndrome" post="(ARDS), different organ failures, and death in the worst"/>
 <result pre="(42). The infected individuals rarely show the intestinal symptoms like" exact="diarrhea" post="that were evident in other coronavirus infections. Patients are"/>
 <result pre="people with a health history, such as those immune-compromised by" exact="HIV infection" post="or by chemotherapy for cancer. Diabetic and asthma patients,"/>
 <result pre="with a health history, such as those immune-compromised by HIV" exact="infection" post="or by chemotherapy for cancer. Diabetic and asthma patients,"/>
 <result pre="by HIV infection or by chemotherapy for cancer. Diabetic and" exact="asthma" post="patients, along with individuals with hypertension, obesity, or heart,"/>
 <result pre="disorders, are also at higher risk if they acquire the" exact="disease" post="(44). Autopsy reports of individuals who died due to"/>
 <result pre="died due to SARS show multi-organ dysfunction, with the highest" exact="viral" post="titers in the lungs and immune cells in circulation,"/>
 <result pre="the lungs and immune cells in circulation, thus damaging the" exact="pulmonary" post="and immune system (45, 46). As opposed to adults,"/>
 <result pre="until adolescence. This could be one of the reasons why" exact="lung fibrosis" post="is observed mainly in younger children. Secondly, differential CD4+"/>
 <result pre="a cross-sectional study of children admitted to US and Canadian" exact="Pediatric" post="Intensive Care Units (PICUs) during March 14-April 3, 2020,"/>
 <result pre="11 children (age 3.7â€&quot;16.6) were admitted experiencing symptoms similar to" exact="Kawasaki disease" post="(KD) along with gastrointestinal issues and elevated inflammatory markers."/>
 <result pre="children (age 3.7â€&quot;16.6) were admitted experiencing symptoms similar to Kawasaki" exact="disease" post="(KD) along with gastrointestinal issues and elevated inflammatory markers."/>
 <result pre="speculating that this could be the reason for KD shock" exact="syndrome" post="(52). Similar cases have been observed in New York,"/>
 <result pre="healthy SARS-CoV-2-positive children started displaying symptoms similar to KD and" exact="toxic shock syndrome," post="thereby needing intensive care (53). Therefore, medical practitioners should"/>
 <result pre="host innate immune cells is impaired during SARS-CoV and MERS-CoV" exact="infection" post="by their non-structural proteins, which affects the overall cytokine"/>
 <result pre="smaller than S protein, it is highly immunogenic, and the" exact="absence of" post="glycosylation sites on it results in N-specific neutralizing antibody"/>
 <result pre="in N-specific neutralizing antibody production at an early stage of" exact="acute" post="infection (59). SARS-CoV-specific IgA, IgG, and IgM antibodies were"/>
 <result pre="N-specific neutralizing antibody production at an early stage of acute" exact="infection" post="(59). SARS-CoV-specific IgA, IgG, and IgM antibodies were detected"/>
 <result pre="was detected after 14 days (63). Another kinetic study of" exact="viral" post="shedding and antibody detection was published in a preprint"/>
 <result pre="also observed that weak responders for IgG antibody had higher" exact="viral" post="clearance than strong responders. This observation suggests that robust"/>
 <result pre="responders. This observation suggests that robust antibody response leads to" exact="disease" post="severity while feeble response is associated with the elimination"/>
 <result pre="The SARS-CoV-2 virus infects through the naso-oral route, followed by" exact="infection" post="in cells expressing ACE2 receptor in the lung, such"/>
 <result pre="in cells expressing ACE2 receptor in the lung, such as" exact="type 2" post="alveolar cells. These viruses dampen anti-viral IFN responses by"/>
 <result pre="the helper T cell subset, stimulation of Th1/Th17 cells with" exact="viral" post="epitopes may lead to aggravated inflammatory responses. This inflammatory"/>
 <result pre="response results in â€œcytokine stormsâ€� that lead to immunopathologies like" exact="pulmonary" post="edema and pneumonia. Cytotoxic T cells recruited to the"/>
 <result pre="and pneumonia. Cytotoxic T cells recruited to the site of" exact="infection" post="try to kill virus-infected cells in the lungs. B"/>
 <result pre="virus-infected cells in the lungs. B cells/plasma cells also recognize" exact="viral" post="proteins and are activated to produce antibodies specific to"/>
 <result pre="to SARS-CoV-2, which may help in deactivating viruses and provide" exact="systemic" post="immunity in different organs. In addition to neutralizing antibodies,"/>
 <result pre="are numerous non-neutralizing antibodies in the system that aid the" exact="infection" post="of immune cells and APCs. Previously existing SARS-CoV antibodies"/>
 <result pre="cells and APCs. Previously existing SARS-CoV antibodies may promote the" exact="viral infection" post="in FcR-expressing cells (66). This ACE2-independent pathway of viral"/>
 <result pre="and APCs. Previously existing SARS-CoV antibodies may promote the viral" exact="infection" post="in FcR-expressing cells (66). This ACE2-independent pathway of viral"/>
 <result pre="viral infection in FcR-expressing cells (66). This ACE2-independent pathway of" exact="viral" post="entry does not result in viral replication; rather, viral"/>
 <result pre="This ACE2-independent pathway of viral entry does not result in" exact="viral" post="replication; rather, viral shedding by macrophages enhances inflammation and"/>
 <result pre="of viral entry does not result in viral replication; rather," exact="viral" post="shedding by macrophages enhances inflammation and tissue injury by"/>
 <result pre="and tissue injury by myeloid cell activation. This mechanism of" exact="viral" post="entry through non-neutralizing antibody that results in aberrant activation"/>
 <result pre="(66, 67). ADE has been observed in a number of" exact="viral" post="infections, including SARS and MERS. In the case of"/>
 <result pre="vaccines and treatment regimens involving antibodies (70). Antigen Presentation During" exact="viral infection," post="T cells also recognize the viral antigens presented by"/>
 <result pre="Antigen Presentation During viral infection, T cells also recognize the" exact="viral" post="antigens presented by MHC class I [MHC; Human Leukocyte"/>
 <result pre="the viral antigens presented by MHC class I [MHC; Human" exact="Leukocyte" post="Antigen (HLA) in humans], which in turn promotes the"/>
 <result pre="the HLA-DRB1*03, HLA-A*02, and HLA-Cw*15 haplotypes are protected from SARS-CoV" exact="infection" post="(74). Similarly, HLA-DRB1*11 and HLA-DQB1*02 were found to be"/>
 <result pre="HLA-DRB1*11 and HLA-DQB1*02 were found to be vulnerable to MERS-CoV" exact="infection" post="(75). Additionally, MHC expression is also found to be"/>
 <result pre="MHC expression is also found to be reduced during the" exact="infection" post="due to epigenetic modifications of downstream molecules (76, 77)."/>
 <result pre="conditions (78). Decrease in MHC expression is also evident in" exact="cancer" post="cells, which is a mechanism by which they evade"/>
 <result pre="evade the immune response by epigenetically modifying calnexin promoter. But" exact="infection" post="with influenza virus in these cancer cells results in"/>
 <result pre="modifying calnexin promoter. But infection with influenza virus in these" exact="cancer" post="cells results in enhanced MHC-I presentation due to the"/>
 <result pre="stabilizes p53 expression and hence augments the immune surveillance of" exact="cancer" post="cells (79). Therefore, molecules that can upregulate chromatin regulators"/>
 <result pre="models by assessing the lung pathology and T-cell response upon" exact="infection" post="in BALB/c and C57BL/6 mice (80, 83). The sequence"/>
 <result pre="immunotherapy by small molecules that can increase the presentation of" exact="viral" post="epitopes. Cytokine Production A rapid and coordinated immune response"/>
 <result pre="epitopes. Cytokine Production A rapid and coordinated immune response during" exact="viral infection" post="leads to enhanced secretion of various cytokines, which acts"/>
 <result pre="Cytokine Production A rapid and coordinated immune response during viral" exact="infection" post="leads to enhanced secretion of various cytokines, which acts"/>
 <result pre="IL-6, and IFN-Î±/-Î³, with reduced anti-inflammatory cytokines (86â€&quot;88). Similarly, MERS-CoV" exact="infection" post="leads to delayed but increased production of IFN-Î± and"/>
 <result pre="Such elevated levels of cytokines were associated with Multi-Organ Dysfunctional" exact="Syndrome" post="(MODS) and ARDS due to the accumulation of numerous"/>
 <result pre="chemokines (IP-10, CCL2/MCP1, CXCL1, CXCL5) were also detected in SARS-CoV-2" exact="infection" post="(96â€&quot;99). In children, the increased inflammatory markers include IL-6,"/>
 <result pre="with anakinra (IL-1 receptor antagonist) in order to stabilize the" exact="respiratory" post="illness and other clinical symptoms (100). Transcriptomic analysis of"/>
 <result pre="P53 signaling molecules were upregulated, suggesting a possible reason for" exact="lymphopenia" post="in these patients (101). Therapeutic measures to control such"/>
 <result pre="for cytokine production. Immune Evasion The most potent antiviral machinery" exact="acquired" post="by immune cells is the secretion of interferons that"/>
 <result pre="immune cells is the secretion of interferons that act as" exact="secondary" post="messengers stimulating the neighboring cells. Most innate immune cells"/>
 <result pre="the host immune response, one of which is by severe" exact="leukopenia" post="and lymphopenia (103â€&quot;105). After gaining entry to the cell,"/>
 <result pre="immune response, one of which is by severe leukopenia and" exact="lymphopenia" post="(103â€&quot;105). After gaining entry to the cell, these viruses"/>
 <result pre="hence its translocation to the nucleus (4, 107, 108). These" exact="viral" post="accessory proteins also inhibit the JAK-STAT pathway, resulting in"/>
 <result pre="promoters (109â€&quot;111) (Figure 3). A new investigation revealed that SARS-CoV-2" exact="infection" post="leads to an overall decrease in the transcription of"/>
 <result pre="decrease in the transcription of antiviral genes because of the" exact="lower" post="production of Type I and III interferons with sufficient"/>
 <result pre="transcription of antiviral genes because of the lower production of" exact="Type I" post="and III interferons with sufficient ISG expression, along with"/>
 <result pre="severity (112). In addition to reduction in T cells, SARS-CoV-2" exact="infection" post="also enhances the exhaustion of effector T cells, decreasing"/>
 <result pre="Figure 3 SARS-CoV-mediated evasion of host innate immune response. The" exact="viral" post="antigens are recognized via different PRRs to elicit the"/>
 <result pre="are endocytosed into the cytosol and are then recognized by" exact="cytosolic" post="PRRs like RIG-I and MDA5. (2) The viral genome,"/>
 <result pre="recognized by cytosolic PRRs like RIG-I and MDA5. (2) The" exact="viral" post="genome, along with different proteins, interacts with MAVS and"/>
 <result pre="and moves inside the nucleus to activate the transcription of" exact="Type I" post="IFNs. (4) Type I IFNs have both autocrine and"/>
 <result pre="nucleus to activate the transcription of Type I IFNs. (4)" exact="Type I" post="IFNs have both autocrine and paracrine mechanisms to activate"/>
 <result pre="in the figure. Together, the production of pro-inflammatory cytokines and" exact="type I" post="IFNs tries to create an antiviral immune microenvironment that"/>
 <result pre="IFNs tries to create an antiviral immune microenvironment that controls" exact="viral" post="synthesis and infection, but the viruses have deployed various"/>
 <result pre="the immune response. RIG-I, Retinoic acid-Inducible Gene I protein; MDA5," exact="Melanoma" post="Differentiation-Associated protein 5; MAVS, Mitochondrial antiviral-signaling protein; M, Membrane"/>
 <result pre="acid-Inducible Gene I protein; MDA5, Melanoma Differentiation-Associated protein 5; MAVS," exact="Mitochondrial" post="antiviral-signaling protein; M, Membrane protein; N, Nucleocapsid; IFNAR, IFNÎ±/Î²"/>
 <result pre="T cells help in destroying the infected cells during subsequent" exact="infection" post="(116, 117). Case studies in recovered SARS patients showed"/>
 <result pre="could be used to target a particular population for rapid" exact="viral" post="clearance. In recent reports, COVID-19 subjects have shown reduced"/>
 <result pre="developed by CRISPR/Cas9 technology that recapitulates the human symptoms upon" exact="infection" post="with SARS-CoV-2 through the intra-nasal route. This tool will"/>
 <result pre="providing intensive care in order to alleviate the symptoms and" exact="discomfort" post="associated with COVID-19. Conservative fluid therapy accompanied by broad-spectrum"/>
 <result pre="to the patients as a protective measure to avoid opportunistic" exact="bacterial infections." post="However, ventilator support for respiration is provided to the"/>
 <result pre="of existing anti-viral drugs against COVID-19 (147, 148), considering the" exact="total" post="time it takes to perform clinical trials and get"/>
 <result pre="receptor Obstructs IL-6-mediated signal transduction. (127) Infliximab TNF Blocks soluble" exact="tumor" post="necrosis factor and signal transduction, which helps maintain remission"/>
 <result pre="Lenzilumab GM-CSF Neutralization antibody for GM-CSF that is essential for" exact="chronic" post="and acute inflammation in COVID-19. (129) Gimsilumab (130) Interferons"/>
 <result pre="Neutralization antibody for GM-CSF that is essential for chronic and" exact="acute" post="inflammation in COVID-19. (129) Gimsilumab (130) Interferons IFNÃŸ-1b Enhances"/>
 <result pre="(131) IFN- Î» (132) SMALL-MOLECULE ANTIVIRAL DRUGS Aurine tricarboxylic acid" exact="Viral" post="RNA polymerase Binds to viral polymerase, and tested against"/>
 <result pre="ANTIVIRAL DRUGS Aurine tricarboxylic acid Viral RNA polymerase Binds to" exact="viral" post="polymerase, and tested against SARS virus in in-vitro culture."/>
 <result pre="and tested against SARS virus in in-vitro culture. (133) Rupintrivir" exact="Viral" post="proteases Protease inhibitor: inactivates 3CLpro and PLpro. (134) Benzopurpurin"/>
 <result pre="inactivates 3CLpro and PLpro. (134) Benzopurpurin B NSP15 endo-ribonuclease Reduces" exact="viral" post="infectivity of SARS virus in cell culture by inhibiting"/>
 <result pre="Angiotensin AT2 receptor AT2 receptor agonist that may improve the" exact="viral" post="damage to the lungs. (134) Î²-D-N4-hydroxycytidine (NHC) Viral RNA"/>
 <result pre="improve the viral damage to the lungs. (134) Î²-D-N4-hydroxycytidine (NHC)" exact="Viral" post="RNA polymerase Inhibits replication of multiple coronaviruses. Can be"/>
 <result pre="kinase Interferes with inflammatory signaling involving Janus kinase. (137) Lopinavir" exact="Viral" post="protease Involved in immature, noninfectious HIV virus particle, and"/>
 <result pre="inhibitor. No positive response in combination with lopinavir. (139) Favilavir" exact="Viral" post="RNA polymerase Purine analog blocking viral RNA synthesis. (140)"/>
 <result pre="with lopinavir. (139) Favilavir Viral RNA polymerase Purine analog blocking" exact="viral" post="RNA synthesis. (140) Remdesivir (141) Ribavirin Guanosine nucleoside binds"/>
 <result pre="SARS-CoV-2 entry. (144, 145) Nitazoxanide Glutathione-S-transferase Alters pH and inhibits" exact="viral" post="maturation. Reported against TB, helminthic, and protozoan infection. (140)"/>
 <result pre="protozoan infection. (140) Umifenovir/arbidol N/A Interacts with aromatic residues of" exact="viral" post="glycoproteins. Is being trialed for prophylactic action against COVID-19."/>
 <result pre="Agents Considering the studies on the molecular mechanism of coronavirus" exact="infection" post="(147), several antiviral drugs could be repurposed for the"/>
 <result pre="and has been tested widely against previous epidemics of coronavirus" exact="infections" post="in both in-vitro and in-vivo models (138, 149â€&quot;151). This"/>
 <result pre="149â€&quot;151). This adenosine analog gets incorporated into the newly synthesized" exact="viral" post="RNA, which inhibits the addition of further nucleotides by"/>
 <result pre="viral RNA, which inhibits the addition of further nucleotides by" exact="viral" post="RNA-dependent RNA polymerase and hence terminates the ongoing transcription."/>
 <result pre="the USA (152). A randomized double-blinded clinical trial on 1,059" exact="adult" post="hospitalized COVID-19 patients was sponsored by the National Institute"/>
 <result pre="patients was sponsored by the National Institute of Allergy and" exact="Infectious" post="Diseases, USA, to further test the potency of intravenously"/>
 <result pre="potential nucleoside analogs that might be useful against novel coronavirus" exact="infection" post="(154). The combinatorial therapy approach of using remdesivir along"/>
 <result pre="(40.1%) as compared to the placebo treatment (6.8%). However, no" exact="cardiovascular" post="disorder or treatment-related major complications were observed (158). Based"/>
 <result pre="on the endosomal acidification, whereby it is presumed to hinder" exact="viral" post="uncapping, it can be observed that it has a"/>
 <result pre="it has a great potential for prophylaxis, not to prevent" exact="infection" post="but to reduce effective viral load in patients and"/>
 <result pre="for prophylaxis, not to prevent infection but to reduce effective" exact="viral" post="load in patients and thus lead to milder disease."/>
 <result pre="beta (IFN-Î²), have been tested in vivo for treating coronavirus" exact="infections" post="(SARS-CoV, MERS-CoV) and have also been used in the"/>
 <result pre="therapies could also be employed as a preventive measure against" exact="viral" post="infections. Many essential proteases, such as chymotrypsin (3C-like protease)"/>
 <result pre="tested further for their potency (163). Plasma Therapy In the" exact="absence of" post="any dependable vaccine or drugs with tested efficacy and"/>
 <result pre="and has been used whenever there are sudden outbreaks of" exact="viral" post="diseases like SARS, MERS, H1N1, H5N1, Ebola, and many"/>
 <result pre="therapy is the only means to provide immediate immunity for" exact="viral" post="clearance, as in the case of SARS-CoV-2. As in"/>
 <result pre="Although a randomized controlled trial is yet to be reported," exact="limited" post="studies in 10 patients have been documented with no"/>
 <result pre="10 patients have been documented with no remission of severe" exact="respiratory" post="afflictions on receiving neutralizing antibodies from 39 convalesced donors"/>
 <result pre="As with transfusion of any blood products, precautionary screening of" exact="infectious" post="agent is warranted in plasma transfusion. Recently, the FDA"/>
 <result pre="points to plausible favorable outcomes in earlier phases of the" exact="disease" post="because in the later, more severe phases, the hyper-immune"/>
 <result pre="later, more severe phases, the hyper-immune response, rather than the" exact="viral" post="load, becomes the more critical pathology. Finally, there are"/>
 <result pre="designing a specific vaccine targeting either the structural proteins or" exact="viral" post="replication process, which eventually results in the inhibition of"/>
 <result pre="viral replication process, which eventually results in the inhibition of" exact="viral" post="growth and its further transmission. The common strategies involve"/>
 <result pre="10 different strains of SARS-CoV-2 without developing any ADE of" exact="infection" post="(176). Various randomized controlled trials (NCT04327206, NCT04328441) are also"/>
 <result pre="has followed a similar approach by using a recombinant adenovirus" exact="type 5" post="(Ad5-nCoV) vector-based vaccine for COVID-19. The full report from"/>
 <result pre="attenuated viruses, for example, complications resulting in lung damage by" exact="infiltrating" post="eosinophils, as seen in in vivo models (179, 180)."/>
 <result pre="be reduced by using TLR4 agonist as an adjuvant (181)." exact="Viral" post="neutralizing antibodies specifically targeting various regions of S, i.e.,"/>
 <result pre="IFN-Î³, which further contributes to conferring protective immunity against SARS-CoV-2" exact="infection" post="(184). Recently, a monoclonal antibody (47D11) has been identified"/>
 <result pre="and this results in elevated production of various cytokines and" exact="type I" post="interferons (IFNs). In the case of prolonged infection, hyperactivation"/>
 <result pre="showed that treatment with recombinant type-1 IFN (rIFN) decreased the" exact="viral" post="RNA level in lungs with a decrease in IFN-stimulating"/>
 <result pre="been previously used for inflammatory conditions and graft vs. host" exact="disease" post="in children and adults, is now being assessed for"/>
 <result pre="control the SARS-CoV-2 pandemic. The fatality rate of SARS-CoV-2 in" exact="lower" post="than those of other coronaviruses that caused catastrophes in"/>
 <result pre="neutralizing antibodies against S protein could enhance the effectiveness of" exact="viral" post="clearance. Among various antivirals and other small molecules that"/>
 <result pre="were thought to be effective, have failed in curing the" exact="disease" post="(139, 196). Cytokine storm being one of the symptoms"/>
 <result pre="the readily available and safe drugs to reduce the rising" exact="infections" post="and COVID-19-related deaths so as to bring life back"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="SC, for the financial support. References References 1.ZhouPYangX-LWangXGHuBZhangLZhangWet al.. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="Air, surface environmental, and personal protective equipment contamination by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient."/>
 <result pre="surface environmental, and personal protective equipment contamination by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA"/>
 <result pre="environmental, and personal protective equipment contamination by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA -"/>
 <result pre="by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a" exact="symptomatic" post="patient. JAMA - J Am Med Assoc. (2020) 323:5â€&quot;7."/>
 <result pre="14:523â€&quot;34. 10.1038/nrmicro.2016.8127344959 5.VerityROkellLCDorigattiIWinskillPWhittakerCImaiNet al.. Estimates of the severity of coronavirus" exact="disease" post="2019 : a model-based analysis. Lancet Infect Dis. (2020)"/>
 <result pre="300:1399â€&quot;404. 10.1126/science.108595212730501 8.WuFZhaoSYuBChenYMWangWSongZGet al.. A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature. (2020) 579:265â€&quot;9. 10.1038/s41586-020-2008-332015508 9.ZhangLLinDSunXCurthUDrostenCSauerheringLet al.."/>
 <result pre="10.1126/science.108595212730501 8.WuFZhaoSYuBChenYMWangWSongZGet al.. A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature. (2020) 579:265â€&quot;9. 10.1038/s41586-020-2008-332015508 9.ZhangLLinDSunXCurthUDrostenCSauerheringLet al.. Crystal"/>
 <result pre="design of improved Î±-ketoamide inhibitors. Science. (2020) 3405:1â€&quot;9. 10.1126/science.abb340532198291 10.YanRZhangYLiYXiaLGuoYZhouQ." exact="Structural" post="basis for the recognition of the SARS-CoV-2 by full-length"/>
 <result pre="2:1444â€&quot;8. 10.1126/science.abb276232132184 11.ZhuNZhangDWangWLiXYangBSongJet al.. A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med. (2020) 382:727â€&quot;33."/>
 <result pre="18:1â€&quot;9. 10.1186/s12967-020-02344-631900168 20.van DorpLAcmanMRichardDShawLPFordCEOrmondLet al.. Emergence of genomic diversity and" exact="recurrent" post="mutations in SARS-CoV-2. Infect Genet Evol. (2020) 83:104351. 10.1016/j.meegid.2020.10435132387564"/>
 <result pre="protein. Adv Exp Med Biol. (1995) 380:359â€&quot;65. 10.1007/978-1-4615-1899-0_588830508 29.ChengPKCWongDATongLKLIpSMLoACTLauCSet al.." exact="Viral" post="shedding patterns of coronavirus in patients with probable severe"/>
 <result pre="Viral shedding patterns of coronavirus in patients with probable severe" exact="acute" post="respiratory syndrome. Lancet. (2004) 363:1699â€&quot;700. 10.1016/S0140-6736(04)16255-715158632 30.ZhangNJiangSDuL. Current advancements"/>
 <result pre="shedding patterns of coronavirus in patients with probable severe acute" exact="respiratory" post="syndrome. Lancet. (2004) 363:1699â€&quot;700. 10.1016/S0140-6736(04)16255-715158632 30.ZhangNJiangSDuL. Current advancements and"/>
 <result pre="Cell Mol Immunol. (2020) 17:3â€&quot;5. 10.1038/s41423-020-0374-232047258 32.SimmonsGReevesJDRennekampAJAmbergSMPieferAJBatesP. Characterization of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc"/>
 <result pre="Mol Immunol. (2020) 17:3â€&quot;5. 10.1038/s41423-020-0374-232047258 32.SimmonsGReevesJDRennekampAJAmbergSMPieferAJBatesP. Characterization of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl"/>
 <result pre="Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated" exact="viral" post="entry. Proc Natl Acad Sci USA. (2004) 101:4240â€&quot;5. 10.1073/pnas.030644610115010527"/>
 <result pre="intracellular localization, and replication complex association of the putative mouse" exact="hepatitis" post="virus RNA-dependent RNA polymerase. J Virol. (2003) 77:10515â€&quot;27. 10.1128/jvi.77.19.10515-10527.200312970436"/>
 <result pre="novel subgenomic RNAs and noncanonical transcription initiation signals of severe" exact="acute" post="respiratory syndrome coronavirus. J Virol. (2005) 79:5288â€&quot;95. 10.1128/jvi.79.9.5288-5295.200515827143 38.PerrierABonninADesmaretsLDanneelsAGoffardARouillÃ©Yet"/>
 <result pre="subgenomic RNAs and noncanonical transcription initiation signals of severe acute" exact="respiratory" post="syndrome coronavirus. J Virol. (2005) 79:5288â€&quot;95. 10.1128/jvi.79.9.5288-5295.200515827143 38.PerrierABonninADesmaretsLDanneelsAGoffardARouillÃ©Yet al.."/>
 <result pre="RNAs and noncanonical transcription initiation signals of severe acute respiratory" exact="syndrome" post="coronavirus. J Virol. (2005) 79:5288â€&quot;95. 10.1128/jvi.79.9.5288-5295.200515827143 38.PerrierABonninADesmaretsLDanneelsAGoffardARouillÃ©Yet al.. The"/>
 <result pre="40.SungnakWHuangNBÃ©cavinCBergMQueenRLitvinukovaMet al.. SARS-CoV-2 entry factors are highly expressed in nasal" exact="epithelial" post="cells together with innate immune genes. Nat Med. (2020)"/>
 <result pre="at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/underlying-conditions.html (accessed April 6, 2020). 42.collab: CDCInfection Control: severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). (2020). Available online at:"/>
 <result pre="https://www.cdc.gov/coronavirus/2019-ncov/hcp/underlying-conditions.html (accessed April 6, 2020). 42.collab: CDCInfection Control: severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). (2020). Available online at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html"/>
 <result pre="(accessed April 6, 2020). 42.collab: CDCInfection Control: severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). (2020). Available online at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html (accessed"/>
 <result pre="lessons learned from SARS and MERS epidemic. Asian Pacific J" exact="allergy" post="Immunol. (2020) 38:1â€&quot;9. 10.12932/AP-200220-077232105090 44.collab: CDCPeople Who Are at"/>
 <result pre="38:1â€&quot;9. 10.12932/AP-200220-077232105090 44.collab: CDCPeople Who Are at Higher Risk for" exact="Severe" post="Illness | Coronavirus | COVID-19. (2020). Available online at:"/>
 <result pre="Available online at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html (accessed April 7, 2020). 45.MazzulliTFarcasGAPoutanenSMWilleyBMLowDEButanyJet al.." exact="Severe" post="acute respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect"/>
 <result pre="online at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html (accessed April 7, 2020). 45.MazzulliTFarcasGAPoutanenSMWilleyBMLowDEButanyJet al.. Severe" exact="acute" post="respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect Dis."/>
 <result pre="at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html (accessed April 7, 2020). 45.MazzulliTFarcasGAPoutanenSMWilleyBMLowDEButanyJet al.. Severe acute" exact="respiratory" post="syndrome-associated coronavirus in lung tissue. Emerg Infect Dis. (2004)"/>
 <result pre="lung tissue. Emerg Infect Dis. (2004) 10:20â€&quot;4. 10.3201/eid1001.03040415078592 46.GuJGongEZhangBZhengJGaoZZhongYet al.." exact="Multiple" post="organ infection and the pathogenesis of SARS. J Exp"/>
 <result pre="Emerg Infect Dis. (2004) 10:20â€&quot;4. 10.3201/eid1001.03040415078592 46.GuJGongEZhangBZhengJGaoZZhongYet al.. Multiple organ" exact="infection" post="and the pathogenesis of SARS. J Exp Med. (2005)"/>
 <result pre="pathogenesis of SARS. J Exp Med. (2005) 202:415â€&quot;24. 10.1084/jem.2005082816043521 47.CentisRScMSARS-CoV-2" exact="Infection" post="in Children. N Engl J Med. (2020) 382:4â€&quot;6. 10.1056/NEJMc121000131800980"/>
 <result pre="Med. (2020) 382:4â€&quot;6. 10.1056/NEJMc121000131800980 48.ZhangZGuoLLuXZhangCWangXHuangLet al.Vulnerability of children with COVID-19" exact="infection" post="and ACE2 profiles in lungs. SSRN. (2020) 1:1â€&quot;18. 10.2139/ssrn.3602441"/>
 <result pre="145:2020. 10.1038/s41390-020-0892-832268343 50.ChenZMFuJFShuQChenYHHuaCZLiFBet al.. Diagnosis and treatment recommendations for pediatric" exact="respiratory" post="infection caused by the 2019 novel coronavirus. World J"/>
 <result pre="10.1038/s41390-020-0892-832268343 50.ChenZMFuJFShuQChenYHHuaCZLiFBet al.. Diagnosis and treatment recommendations for pediatric respiratory" exact="infection" post="caused by the 2019 novel coronavirus. World J Pediatr."/>
 <result pre="10.1007/s12519-020-00345-532026148 51.ShekerdemianLSMahmoodNRWolfeKKRiggsBJRossCEMcKiernanCAet al.. Characteristics and outcomes of children with coronavirus" exact="disease" post="2019 (COVID-19) infection admitted to US and canadian pediatric"/>
 <result pre="Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19)" exact="infection" post="admitted to US and canadian pediatric intensive care units."/>
 <result pre="units. JAMA Pediatr. (2020) 2019:1â€&quot;6. 10.1001/jamapediatrics.2020.194832392288 52.ToubianaJPoiraultCCorsiaABajolleFFourgeaudJAngoulvantFet al.. Outbreak of" exact="Kawasaki disease" post="in children during COVID-19 pandemic: a prospective observational study"/>
 <result pre="JAMA Pediatr. (2020) 2019:1â€&quot;6. 10.1001/jamapediatrics.2020.194832392288 52.ToubianaJPoiraultCCorsiaABajolleFFourgeaudJAngoulvantFet al.. Outbreak of Kawasaki" exact="disease" post="in children during COVID-19 pandemic: a prospective observational study"/>
 <result pre="1â€&quot;21. 10.1101/2020.05.10.2009739432493739 53.WaltuchTGillPZinnsLEWhitneyRTokarskiJTsungJWet al.. Features of COVID-19 post-infectious cytokine release" exact="syndrome" post="in children presenting to the emergency department. Am J"/>
 <result pre="print].32471782 54.Le BonAToughDF. Links between innate and adaptive immunity via" exact="type I" post="interferon. Curr Opin Immunol. (2002) 14:432â€&quot;6. 10.1016/S0952-7915(02)00354-012088676 55.ThielVWeberF. Interferon"/>
 <result pre="SARS-CoV regulates immune function-related gene expression in human monocytic cells." exact="Viral" post="Immunol. (2012) 25:277â€&quot;88. 10.1089/vim.2011.009922876772 57.TanYJGohPYFieldingBCShenSChouCFFuJLet al.. Profiles of antibody"/>
 <result pre="25:277â€&quot;88. 10.1089/vim.2011.009922876772 57.TanYJGohPYFieldingBCShenSChouCFFuJLet al.. Profiles of antibody responses against severe" exact="acute" post="respiratory syndrome coronavirus recombinant proteins and their potential use"/>
 <result pre="10.1089/vim.2011.009922876772 57.TanYJGohPYFieldingBCShenSChouCFFuJLet al.. Profiles of antibody responses against severe acute" exact="respiratory" post="syndrome coronavirus recombinant proteins and their potential use as"/>
 <result pre="57.TanYJGohPYFieldingBCShenSChouCFFuJLet al.. Profiles of antibody responses against severe acute respiratory" exact="syndrome" post="coronavirus recombinant proteins and their potential use as diagnostic"/>
 <result pre="J Immunol. (2008) 181:5490â€&quot;500. 10.4049/jimmunol.181.8.549018832706 62.ToKKTakOTsangYLeungWTamARWuTet al.. Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
 <result pre="181:5490â€&quot;500. 10.4049/jimmunol.181.8.549018832706 62.ToKKTakOTsangYLeungWTamARWuTet al.. Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2 : an observational cohort study. Lancet Infect"/>
 <result pre="63.GuoLRenLYangSXiaoMChangDYangFet al.. Profiling early humoral response to diagnose novel coronavirus" exact="disease" post="(COVID-19). Clin Infect Dis. (2020) 21:1â€&quot;8. 10.1093/cid/ciaa31032198501 64.TanWLuYZhangJWangJDanYTanZet al.."/>
 <result pre="disease (COVID-19). Clin Infect Dis. (2020) 21:1â€&quot;8. 10.1093/cid/ciaa31032198501 64.TanWLuYZhangJWangJDanYTanZet al.." exact="Viral" post="kinetics and antibody responses in patients with COVID-19. medRxiv."/>
 <result pre="(2020) 1â€&quot;24. 10.20944/preprints202003.0138.v1 68.YipMLeungHLiPCheungCDutryILiDet al.. Antibody-dependent enhancement of SARS coronavirus" exact="infection" post="and its role in the pathogenesis of SARS. Hong"/>
 <result pre="cytotoxic t-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe" exact="acute" post="respiratory syndrome coronavirus nucleocapsid protein. J Virol. (2010) 84:11849â€&quot;57."/>
 <result pre="t-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute" exact="respiratory" post="syndrome coronavirus nucleocapsid protein. J Virol. (2010) 84:11849â€&quot;57. 10.1128/jvi.01464-1020844028"/>
 <result pre="epitope stabilized by intrachain hydrogen bonds from severe acute respiratory" exact="syndrome" post="coronavirus nucleocapsid protein. J Virol. (2010) 84:11849â€&quot;57. 10.1128/jvi.01464-1020844028 72.KeichoNItoyamaSKashiwaseKPhiNCLongHTHaLDet"/>
 <result pre="Association of human leukocyte antigen class II alleles with severe" exact="acute" post="respiratory syndrome in the Vietnamese population. Hum Immunol. (2009)"/>
 <result pre="of human leukocyte antigen class II alleles with severe acute" exact="respiratory" post="syndrome in the Vietnamese population. Hum Immunol. (2009) 70:527â€&quot;31."/>
 <result pre="human leukocyte antigen class II alleles with severe acute respiratory" exact="syndrome" post="in the Vietnamese population. Hum Immunol. (2009) 70:527â€&quot;31. 10.1016/j.humimm.2009.05.00619445991"/>
 <result pre="70:527â€&quot;31. 10.1016/j.humimm.2009.05.00619445991 73.ChenYMALiangSYShihYPChenCYLeeYMChangLet al.. Epidemiological and genetic correlates of severe" exact="acute" post="respiratory syndrome coronavirus infection in the hospital with the"/>
 <result pre="10.1016/j.humimm.2009.05.00619445991 73.ChenYMALiangSYShihYPChenCYLeeYMChangLet al.. Epidemiological and genetic correlates of severe acute" exact="respiratory" post="syndrome coronavirus infection in the hospital with the highest"/>
 <result pre="73.ChenYMALiangSYShihYPChenCYLeeYMChangLet al.. Epidemiological and genetic correlates of severe acute respiratory" exact="syndrome" post="coronavirus infection in the hospital with the highest nosocomial"/>
 <result pre="Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus" exact="infection" post="in the hospital with the highest nosocomial infection rate"/>
 <result pre="respiratory syndrome coronavirus infection in the hospital with the highest" exact="nosocomial infection" post="rate in Taiwan in 2003. J Clin Microbiol. (2006)"/>
 <result pre="syndrome coronavirus infection in the hospital with the highest nosocomial" exact="infection" post="rate in Taiwan in 2003. J Clin Microbiol. (2006)"/>
 <result pre="II DR 0301 genotypes are associated with resistance to severe" exact="acute" post="respiratory syndrome (SARS) infection. Viral Immunol. (2011) 24:421â€&quot;6. 10.1089/vim.2011.002421958371"/>
 <result pre="DR 0301 genotypes are associated with resistance to severe acute" exact="respiratory" post="syndrome (SARS) infection. Viral Immunol. (2011) 24:421â€&quot;6. 10.1089/vim.2011.002421958371 75.HajeerAHBalkhyHJohaniSYousefMZArabiY."/>
 <result pre="0301 genotypes are associated with resistance to severe acute respiratory" exact="syndrome" post="(SARS) infection. Viral Immunol. (2011) 24:421â€&quot;6. 10.1089/vim.2011.002421958371 75.HajeerAHBalkhyHJohaniSYousefMZArabiY. Association"/>
 <result pre="associated with resistance to severe acute respiratory syndrome (SARS) infection." exact="Viral" post="Immunol. (2011) 24:421â€&quot;6. 10.1089/vim.2011.002421958371 75.HajeerAHBalkhyHJohaniSYousefMZArabiY. Association of human leukocyte"/>
 <result pre="human leukocyte antigen class II alleles with severe Middle East" exact="respiratory" post="syndrome-coronavirus infection. Ann Thorac Med. (2016) 11:211â€&quot;3. 10.4103/1817-1737.18575627512511 76.JossetLMenacheryVDGralinskiLEAgnihothramSSovaPCarterVSet"/>
 <result pre="Med. (2016) 11:211â€&quot;3. 10.4103/1817-1737.18575627512511 76.JossetLMenacheryVDGralinskiLEAgnihothramSSovaPCarterVSet al.. Cell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
 <result pre="Proc Natl Acad Sci USA. (2018) 115:E1012â€&quot;21. 10.1073/pnas.170692811529339515 78.Giamarellos-bourboulisEJNeteaMGRovinaNKoulourisNGogosCKoutsoukouAet al.." exact="Complex" post="immune dysregulation in COVID-19 patients with severe respiratory failure."/>
 <result pre="78.Giamarellos-bourboulisEJNeteaMGRovinaNKoulourisNGogosCKoutsoukouAet al.. Complex immune dysregulation in COVID-19 patients with severe" exact="respiratory" post="failure. Cell Host Microbe. (2020) 27:1â€&quot;9. 10.1016/j.chom.2020.04.00931951820 79.AlamATayeNPatelSThubeMMullickJShahVKet al.."/>
 <result pre="Microbe. (2020) 27:1â€&quot;9. 10.1016/j.chom.2020.04.00931951820 79.AlamATayeNPatelSThubeMMullickJShahVKet al.. SMAR1 favors immunosurveillance of" exact="cancer" post="cells by modulating calnexin and MHC I expression. Neoplasia"/>
 <result pre="80.ZhaoJZhaoJPerlmanS. T cell responses are required for protection from clinical" exact="disease" post="and for virus clearance in severe acute respiratory syndrome"/>
 <result pre="protection from clinical disease and for virus clearance in severe" exact="acute" post="respiratory syndrome coronavirus-infected mice. J Virol. (2010) 84:9318â€&quot;25. 10.1128/jvi.01049-1020610717"/>
 <result pre="from clinical disease and for virus clearance in severe acute" exact="respiratory" post="syndrome coronavirus-infected mice. J Virol. (2010) 84:9318â€&quot;25. 10.1128/jvi.01049-1020610717 81.HuangJCaoYDuJBuXMaRWuC."/>
 <result pre="clinical disease and for virus clearance in severe acute respiratory" exact="syndrome" post="coronavirus-infected mice. J Virol. (2010) 84:9318â€&quot;25. 10.1128/jvi.01049-1020610717 81.HuangJCaoYDuJBuXMaRWuC. Priming"/>
 <result pre="(2007) 25:6981â€&quot;91. 10.1016/j.vaccine.2007.06.04717709158 82.ZhaoJAlshukairiANBaharoonSAAhmedWABokhariAANehdiAMet al.. Recovery from the Middle East" exact="respiratory" post="syndrome is associated with antibody and T cell responses."/>
 <result pre="25:6981â€&quot;91. 10.1016/j.vaccine.2007.06.04717709158 82.ZhaoJAlshukairiANBaharoonSAAhmedWABokhariAANehdiAMet al.. Recovery from the Middle East respiratory" exact="syndrome" post="is associated with antibody and T cell responses. Sci"/>
 <result pre="T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19" exact="disease" post="and unexposed individuals. Cell. (2020) 181:1489â€&quot;501. 10.1016/j.cell.2020.05.01532473127 86.CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJ. Human"/>
 <result pre="individuals. Cell. (2020) 181:1489â€&quot;501. 10.1016/j.cell.2020.05.01532473127 86.CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJ. Human immunopathogenesis of severe" exact="acute" post="respiratory syndrome (SARS). Virus Res. (2008) 133:13â€&quot;9. 10.1016/j.virusres.2007.02.01417374415 87.WongCKLamCWKWuAKLIpWKLeeNLSChanIHSet"/>
 <result pre="Cell. (2020) 181:1489â€&quot;501. 10.1016/j.cell.2020.05.01532473127 86.CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJ. Human immunopathogenesis of severe acute" exact="respiratory" post="syndrome (SARS). Virus Res. (2008) 133:13â€&quot;9. 10.1016/j.virusres.2007.02.01417374415 87.WongCKLamCWKWuAKLIpWKLeeNLSChanIHSet al.."/>
 <result pre="(2020) 181:1489â€&quot;501. 10.1016/j.cell.2020.05.01532473127 86.CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJ. Human immunopathogenesis of severe acute respiratory" exact="syndrome" post="(SARS). Virus Res. (2008) 133:13â€&quot;9. 10.1016/j.virusres.2007.02.01417374415 87.WongCKLamCWKWuAKLIpWKLeeNLSChanIHSet al.. Plasma"/>
 <result pre="10.1016/j.virusres.2007.02.01417374415 87.WongCKLamCWKWuAKLIpWKLeeNLSChanIHSet al.. Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndrome. Clin Exp Immunol. (2004) 136:95â€&quot;103. 10.1111/j.1365-2249.2004.02415.x15030519 88.ChienJ-YHsuehP-RChengW-CYuC-JYangP-C."/>
 <result pre="87.WongCKLamCWKWuAKLIpWKLeeNLSChanIHSet al.. Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndrome. Clin Exp Immunol. (2004) 136:95â€&quot;103. 10.1111/j.1365-2249.2004.02415.x15030519 88.ChienJ-YHsuehP-RChengW-CYuC-JYangP-C. Temporal"/>
 <result pre="(2004) 136:95â€&quot;103. 10.1111/j.1365-2249.2004.02415.x15030519 88.ChienJ-YHsuehP-RChengW-CYuC-JYangP-C. Temporal changes in cytokine/chemokine profiles and" exact="pulmonary" post="involvement in severe acute respiratory syndrome. Respirology. (2006) 11:715â€&quot;22."/>
 <result pre="Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe" exact="acute" post="respiratory syndrome. Respirology. (2006) 11:715â€&quot;22. 10.1111/j.1440-1843.2006.00942.x17052299 89.LauSKPLauCCYChanKHLiCPYChenHJinDYet al.. Delayed"/>
 <result pre="changes in cytokine/chemokine profiles and pulmonary involvement in severe acute" exact="respiratory" post="syndrome. Respirology. (2006) 11:715â€&quot;22. 10.1111/j.1440-1843.2006.00942.x17052299 89.LauSKPLauCCYChanKHLiCPYChenHJinDYet al.. Delayed induction"/>
 <result pre="severe acute respiratory syndrome. Respirology. (2006) 11:715â€&quot;22. 10.1111/j.1440-1843.2006.00942.x17052299 89.LauSKPLauCCYChanKHLiCPYChenHJinDYet al.." exact="Delayed" post="induction of proinflammatory cytokines and suppression of innate antiviral"/>
 <result pre="suppression of innate antiviral response by the novel Middle East" exact="respiratory" post="syndrome coronavirus: implications for pathogenesis and treatment. J Gen"/>
 <result pre="of innate antiviral response by the novel Middle East respiratory" exact="syndrome" post="coronavirus: implications for pathogenesis and treatment. J Gen Virol."/>
 <result pre="(2013) 94:2679â€&quot;90. 10.1099/vir.0.055533-024077366 90.ZhouJChuHLiCWongBHYChengZSPoonVKMet al.. Active replication of middle east" exact="respiratory" post="syndrome coronavirus and aberrant induction of inflammatory cytokines and"/>
 <result pre="94:2679â€&quot;90. 10.1099/vir.0.055533-024077366 90.ZhouJChuHLiCWongBHYChengZSPoonVKMet al.. Active replication of middle east respiratory" exact="syndrome" post="coronavirus and aberrant induction of inflammatory cytokines and chemokines"/>
 <result pre="IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomes. J Clin Invest. (2019) 129:3625â€&quot;39. 10.1172/JCI12636331355779 92.NgDLAl HosaniFKeatingMKGerberSIJonesTLMetcalfeMGet"/>
 <result pre="and ultrastructural findings of a fatal case of middle east" exact="respiratory" post="syndrome coronavirus infection in the United Arab Emirates, April"/>
 <result pre="ultrastructural findings of a fatal case of middle east respiratory" exact="syndrome" post="coronavirus infection in the United Arab Emirates, April 2014."/>
 <result pre="of a fatal case of middle east respiratory syndrome coronavirus" exact="infection" post="in the United Arab Emirates, April 2014. Am J"/>
 <result pre="Pathol. (2016) 186:652â€&quot;8. 10.1016/j.ajpath.2015.10.02426857507 93.KongSLChuiPLimBSalto-TellezM. Elucidating the molecular physiopathology of" exact="acute" post="respiratory distress syndrome in severe acute respiratory syndrome patients."/>
 <result pre="(2016) 186:652â€&quot;8. 10.1016/j.ajpath.2015.10.02426857507 93.KongSLChuiPLimBSalto-TellezM. Elucidating the molecular physiopathology of acute" exact="respiratory" post="distress syndrome in severe acute respiratory syndrome patients. Virus"/>
 <result pre="10.1016/j.ajpath.2015.10.02426857507 93.KongSLChuiPLimBSalto-TellezM. Elucidating the molecular physiopathology of acute respiratory distress" exact="syndrome" post="in severe acute respiratory syndrome patients. Virus Res. (2009)"/>
 <result pre="the molecular physiopathology of acute respiratory distress syndrome in severe" exact="acute" post="respiratory syndrome patients. Virus Res. (2009) 145:260â€&quot;9. 10.1016/j.virusres.2009.07.01419635508 94.DiaoBWangCTanYChenXLiuYNingLet"/>
 <result pre="molecular physiopathology of acute respiratory distress syndrome in severe acute" exact="respiratory" post="syndrome patients. Virus Res. (2009) 145:260â€&quot;9. 10.1016/j.virusres.2009.07.01419635508 94.DiaoBWangCTanYChenXLiuYNingLet al.."/>
 <result pre="physiopathology of acute respiratory distress syndrome in severe acute respiratory" exact="syndrome" post="patients. Virus Res. (2009) 145:260â€&quot;9. 10.1016/j.virusres.2009.07.01419635508 94.DiaoBWangCTanYChenXLiuYNingLet al.. Reduction"/>
 <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19). Front Immunol. (2020) 2019:1â€&quot;14. 10.3389/fimmu.2020.0082732425950 95.ZheXuLeiShiYijinWangJiyuanZhangLeiHuangChaoZhanget al.."/>
 <result pre="2019:1â€&quot;14. 10.3389/fimmu.2020.0082732425950 95.ZheXuLeiShiYijinWangJiyuanZhangLeiHuangChaoZhanget al.. Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir Med. (2020) 8:420â€&quot;2. 10.1016/S2213-2600(20)30076-X32085846"/>
 <result pre="10.3389/fimmu.2020.0082732425950 95.ZheXuLeiShiYijinWangJiyuanZhangLeiHuangChaoZhanget al.. Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir Med. (2020) 8:420â€&quot;2. 10.1016/S2213-2600(20)30076-X32085846 96.MehtaPMcauleyDFBrownMSanchezETattersallRSMansonJJ."/>
 <result pre="(2020) 7:1â€&quot;5. 10.1093/nsr/nwaa041 98.WenZhangYanZhaoFengchunZhangQianWangTaishengLiZhengyinLiuet al.. Anti-inflammation treatment of severe coronavirus" exact="disease" post="2019 (COVID-19): from the perspective of clinical immunologists from"/>
 <result pre="Novel paediatric presentation of COVID-19 with ARDS and cytokine storm" exact="syndrome" post="without respiratory symptoms. Lancet Rheumatol. (2020) 2:19â€&quot;21. 10.1016/s2665-9913(20)30137-532427161 101.XiongYLiuYCaoLWangDGuoMJiangAet"/>
 <result pre="presentation of COVID-19 with ARDS and cytokine storm syndrome without" exact="respiratory" post="symptoms. Lancet Rheumatol. (2020) 2:19â€&quot;21. 10.1016/s2665-9913(20)30137-532427161 101.XiongYLiuYCaoLWangDGuoMJiangAet al.. Transcriptomic"/>
 <result pre="10.1016/s2665-9913(20)30137-532427161 101.XiongYLiuYCaoLWangDGuoMJiangAet al.. Transcriptomic characteristics of bronchoalveolar lavage fluid and" exact="peripheral" post="blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect."/>
 <result pre="24:534â€&quot;9. 10.1016/j.it.2003.08.00614552837 103.WongRSMWuAToKFLeeNLamCWKWongCKet al.. Haematological manifestations in patients with severe" exact="acute" post="respiratory syndrome:retrospective analysis. (2003) 326:1358â€&quot;62. 10.1136/bmj.326.7403.135812816821 104.LiTQiuZZhangLHanYHeWLiuZet al.. Significant"/>
 <result pre="10.1016/j.it.2003.08.00614552837 103.WongRSMWuAToKFLeeNLamCWKWongCKet al.. Haematological manifestations in patients with severe acute" exact="respiratory" post="syndrome:retrospective analysis. (2003) 326:1358â€&quot;62. 10.1136/bmj.326.7403.135812816821 104.LiTQiuZZhangLHanYHeWLiuZet al.. Significant changes"/>
 <result pre="syndrome:retrospective analysis. (2003) 326:1358â€&quot;62. 10.1136/bmj.326.7403.135812816821 104.LiTQiuZZhangLHanYHeWLiuZet al.. Significant changes of" exact="peripheral" post="T lymphocyte subsets in patients with severe acute respiratory"/>
 <result pre="changes of peripheral T lymphocyte subsets in patients with severe" exact="acute" post="respiratory syndrome. J Infect Dis. (2004) 189:4â€&quot;7. 10.1086/38153514767818 105.ZakiAMvan"/>
 <result pre="of peripheral T lymphocyte subsets in patients with severe acute" exact="respiratory" post="syndrome. J Infect Dis. (2004) 189:4â€&quot;7. 10.1086/38153514767818 105.ZakiAMvan BoheemenSBestebroerTMOsterhausADMEFouchierRAM."/>
 <result pre="BoheemenSBestebroerTMOsterhausADMEFouchierRAM. Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia. N Engl J Med. (2012) 367:1814â€&quot;20."/>
 <result pre="ORF 4a, ORF 4b, and ORF 5 of Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell."/>
 <result pre="4a, ORF 4b, and ORF 5 of Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell. (2013)"/>
 <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists." exact="Protein" post="Cell. (2013) 4:951â€&quot;61. 10.1007/s13238-013-3096-824318862 107.SignalingN-BFriemanMRatiaKJohnstonREMesecarADBaricRSSevere acute respiratory syndrome coronavirus"/>
 <result pre="are potent interferon antagonists. Protein Cell. (2013) 4:951â€&quot;61. 10.1007/s13238-013-3096-824318862 107.SignalingN-BFriemanMRatiaKJohnstonREMesecarADBaricRSSevere" exact="acute" post="respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic"/>
 <result pre="potent interferon antagonists. Protein Cell. (2013) 4:951â€&quot;61. 10.1007/s13238-013-3096-824318862 107.SignalingN-BFriemanMRatiaKJohnstonREMesecarADBaricRSSevere acute" exact="respiratory" post="syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain"/>
 <result pre="interferon antagonists. Protein Cell. (2013) 4:951â€&quot;61. 10.1007/s13238-013-3096-824318862 107.SignalingN-BFriemanMRatiaKJohnstonREMesecarADBaricRSSevere acute respiratory" exact="syndrome" post="coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate"/>
 <result pre="innate immunity by the papain-like protease domain of the severe" exact="acute" post="respiratory syndrome coronavirus. J Biol Chem. (2007) 282:32208â€&quot;21. 10.1074/jbc.M70487020017761676"/>
 <result pre="immunity by the papain-like protease domain of the severe acute" exact="respiratory" post="syndrome coronavirus. J Biol Chem. (2007) 282:32208â€&quot;21. 10.1074/jbc.M70487020017761676 109.FreundtECYuLParkELenardoMJXuX-N."/>
 <result pre="by the papain-like protease domain of the severe acute respiratory" exact="syndrome" post="coronavirus. J Biol Chem. (2007) 282:32208â€&quot;21. 10.1074/jbc.M70487020017761676 109.FreundtECYuLParkELenardoMJXuX-N. Molecular"/>
 <result pre="10.1074/jbc.M70487020017761676 109.FreundtECYuLParkELenardoMJXuX-N. Molecular determinants for subcellular localization of the severe" exact="acute" post="respiratory syndrome coronavirus open reading frame 3b protein. J"/>
 <result pre="109.FreundtECYuLParkELenardoMJXuX-N. Molecular determinants for subcellular localization of the severe acute" exact="respiratory" post="syndrome coronavirus open reading frame 3b protein. J Virol."/>
 <result pre="Molecular determinants for subcellular localization of the severe acute respiratory" exact="syndrome" post="coronavirus open reading frame 3b protein. J Virol. (2009)"/>
 <result pre="reading frame 3b protein. J Virol. (2009) 83:6631â€&quot;40. 10.1128/jvi.00367-0919403678 110.Kopecky-BrombergSAMartinez-SobridoLFriemanMBaricRAPaleseP." exact="Severe" post="acute respiratory syndrome coronavirus open reading frame (ORF) 3b,"/>
 <result pre="frame 3b protein. J Virol. (2009) 83:6631â€&quot;40. 10.1128/jvi.00367-0919403678 110.Kopecky-BrombergSAMartinez-SobridoLFriemanMBaricRAPaleseP. Severe" exact="acute" post="respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF"/>
 <result pre="3b protein. J Virol. (2009) 83:6631â€&quot;40. 10.1128/jvi.00367-0919403678 110.Kopecky-BrombergSAMartinez-SobridoLFriemanMBaricRAPaleseP. Severe acute" exact="respiratory" post="syndrome coronavirus open reading frame (ORF) 3b, ORF 6,"/>
 <result pre="protein. J Virol. (2009) 83:6631â€&quot;40. 10.1128/jvi.00367-0919403678 110.Kopecky-BrombergSAMartinez-SobridoLFriemanMBaricRAPaleseP. Severe acute respiratory" exact="syndrome" post="coronavirus open reading frame (ORF) 3b, ORF 6, and"/>
 <result pre="development of COVID-19. Cell. (2020) 181:1036â€&quot;45. e1-e9. 10.1016/j.cell.2020.04.02632416070 113.ZhengHZhangMYangC-XZhangNWangX-CYangX-Pet al.." exact="Elevated" post="exhaustion levels and reduced functional diversity of T cells"/>
 <result pre="exhaustion levels and reduced functional diversity of T cells in" exact="peripheral" post="blood may predict severe progression in COVID-19 patients. Cell"/>
 <result pre="infection. Arch Virol. (2009) 154:1093â€&quot;9. 10.1007/s00705-009-0409-619526193 119.TangFQuanYXinZ-TWrammertJMaM-JLvHet al.. Lack of" exact="peripheral" post="memory B cell responses in recovered patients with severe"/>
 <result pre="peripheral memory B cell responses in recovered patients with severe" exact="acute" post="respiratory syndrome: a six-year follow-up study. J Immunol. (2011)"/>
 <result pre="memory B cell responses in recovered patients with severe acute" exact="respiratory" post="syndrome: a six-year follow-up study. J Immunol. (2011) 186:7264â€&quot;8."/>
 <result pre="Airway memory CD4+ T cells mediate protective immunity against emerging" exact="respiratory" post="coronaviruses. Immunity. (2016) 44:1379â€&quot;91. 10.1016/j.immuni.2016.05.00627287409 122.SunSChenQGuHYangGWangYHuangXet al.. A mouse"/>
 <result pre="(2016) 44:1379â€&quot;91. 10.1016/j.immuni.2016.05.00627287409 122.SunSChenQGuHYangGWangYHuangXet al.. A mouse model of SARS-CoV-2" exact="infection" post="and pathogenesis. Cell Host Microbe. (2020) 28:124â€&quot;33.e4. 10.1016/j.chom.2020.05.02032485164 123.ZumlaAChanJFWAzharEIHuiDSCYuenKY."/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version). Mil Med Res. (2020) 7:1â€&quot;23. 10.1186/s40779-020-0233-631928528 125.ZhuZChakrabortiSHeYRobertsASheahanTXiaoDet"/>
 <result pre="neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the" exact="viral" post="spike glycoprotein. Sci Transl Med. (2014) 6:234ra59. 10.1126/scitranslmed.300814024778414 127.ZhangCWuZLiJ-WZhaoHWangG-Q."/>
 <result pre="Sci Transl Med. (2014) 6:234ra59. 10.1126/scitranslmed.300814024778414 127.ZhangCWuZLiJ-WZhaoHWangG-Q. The cytokine release" exact="syndrome" post="(CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist"/>
 <result pre="Int J Antimicrob Agents. (2020) 55:105954. 10.1016/j.ijantimicag.2020.10595432234467 128.MonteleoneGSarzi-PuttiniPCArdizzoneS. Preventing COVID-19-induced" exact="pneumonia" post="with anticytokine therapy. The Lancet Rheumatogy. (2020) 2:e255â€&quot;6. 10.1016/S2665-9913(20)30092-832368737"/>
 <result pre="(2020). Available online at: https://www.altasciences.com/press-release/altasciences-completes-phase-i-study-gimsilumab-ards-covid-19 (accessed April 9, 2020). 131.SallardELescureFXYazdanpanahYMentreFPeiffer-SmadjaN." exact="Type 1" post="interferons as a potential treatment against COVID-19. Antiviral Res."/>
 <result pre="Antiviral Res. (2020) 178:1â€&quot;4. 10.1016/j.antiviral.2020.10479132275914 132.Prokunina-OlssonLAlphonseNDickensonREDurbinJEGlennJSHartmannRet al.. COVID-19 and emerging" exact="viral" post="infections: the case for interferon lambda. J Exp Med."/>
 <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoV. ChemBioChem. (2020) 21:730â€&quot;8. 10.1002/cbic.20200004732022370"/>
 <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoV. ChemBioChem. (2020) 21:730â€&quot;8. 10.1002/cbic.20200004732022370 134.LiuCZhouQLiYGarnerLVWatkinsSPCarterLJet"/>
 <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoV. ChemBioChem. (2020) 21:730â€&quot;8. 10.1002/cbic.20200004732022370 134.LiuCZhouQLiYGarnerLVWatkinsSPCarterLJet al.."/>
 <result pre="An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway" exact="epithelial" post="cell cultures and multiple coronaviruses in mice. Sci Transl"/>
 <result pre="5883:1â€&quot;21. 10.1126/scitranslmed.abb588332253226 137.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAet al.. Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease. Lancet. (2020) 395:e30â€&quot;e31. 10.1016/S0140-6736(20)30304-432032529 138.SheahanTPSimsACLeistSRSchÃ¤ferAWonJBrownAJet al.. Comparative"/>
 <result pre="10.1126/scitranslmed.abb588332253226 137.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAet al.. Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease. Lancet. (2020) 395:e30â€&quot;e31. 10.1016/S0140-6736(20)30304-432032529 138.SheahanTPSimsACLeistSRSchÃ¤ferAWonJBrownAJet al.. Comparative therapeutic"/>
 <result pre="for new enemy: drug repurposing for treatment of newly emerging" exact="viral" post="diseases. Virol Sin. (2020) 35:12250. 10.1007/s12250-020-00204-732048130 141.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir"/>
 <result pre="142.OmraniASSaadMMBaigKBahloulAAbdul-MatinMAlaidaroosAYet al.. Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort study. Lancet Infect"/>
 <result pre="al.. Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort study. Lancet Infect Dis."/>
 <result pre="https://clinicaltrials.gov/ct2/show/NCT04252885 (accessed April 10, 2020). 147.GronebergDAHilgenfeldRZabelP. Molecular mechanisms of severe" exact="acute" post="respiratory syndrome (SARS). Respir Res. (2005) 6:1â€&quot;16. 10.1186/1465-9921-6-815631627 148.WanYShangJGrahamRBaricRSLiF."/>
 <result pre="(accessed April 10, 2020). 147.GronebergDAHilgenfeldRZabelP. Molecular mechanisms of severe acute" exact="respiratory" post="syndrome (SARS). Respir Res. (2005) 6:1â€&quot;16. 10.1186/1465-9921-6-815631627 148.WanYShangJGrahamRBaricRSLiF. Receptor"/>
 <result pre="April 10, 2020). 147.GronebergDAHilgenfeldRZabelP. Molecular mechanisms of severe acute respiratory" exact="syndrome" post="(SARS). Respir Res. (2005) 6:1â€&quot;16. 10.1186/1465-9921-6-815631627 148.WanYShangJGrahamRBaricRSLiF. Receptor recognition"/>
 <result pre="Sci USA. (2020) 117:6771â€&quot;76. 10.1073/pnas.192208311732054787 151.LoMKFeldmannFGaryJMJordanRBannisterRCroninJet al.. Remdesivir (GS-5734) protects" exact="African" post="green monkeys from Nipah virus challenge. Sci Transl Med."/>
 <result pre="156.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.. Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. (2005) 2:1â€&quot;10. 10.1186/1743-422X-2-6915631631 157.SavarinoABoelaertJRCassoneAMajoriGCaudaR. Effects"/>
 <result pre="Virol J. (2005) 2:1â€&quot;10. 10.1186/1743-422X-2-6915631631 157.SavarinoABoelaertJRCassoneAMajoriGCaudaR. Effects of chloroquine on" exact="viral" post="infections: an old drug against today's diseases?Lancet Infect Dis."/>
 <result pre="(2020) 1â€&quot;9. 10.1056/NEJMoa2016638 159.ArabiYMAlothmanABalkhyHHAl-DawoodAAlJohaniSAl HarbiSet al.. Treatment of Middle East" exact="Respiratory" post="Syndrome with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE"/>
 <result pre="1â€&quot;9. 10.1056/NEJMoa2016638 159.ArabiYMAlothmanABalkhyHHAl-DawoodAAlJohaniSAl HarbiSet al.. Treatment of Middle East Respiratory" exact="Syndrome" post="with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE trial):"/>
 <result pre="Cinanserin is an inhibitor of the 3c-like proteinase of severe" exact="acute" post="respiratory syndrome coronavirus and strongly reduces virus replication in"/>
 <result pre="is an inhibitor of the 3c-like proteinase of severe acute" exact="respiratory" post="syndrome coronavirus and strongly reduces virus replication in vitro."/>
 <result pre="an inhibitor of the 3c-like proteinase of severe acute respiratory" exact="syndrome" post="coronavirus and strongly reduces virus replication in vitro. J"/>
 <result pre="al.. Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe" exact="acute" post="respiratory syndrome coronavirus. Biol Pharm Bull. (2012) 35:2036â€&quot;42. 10.1248/bpb.b12-0062322971649"/>
 <result pre="Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute" exact="respiratory" post="syndrome coronavirus. Biol Pharm Bull. (2012) 35:2036â€&quot;42. 10.1248/bpb.b12-0062322971649 163.ZhouYHouYShenJHuangYMartinWChengF."/>
 <result pre="from Alnus japonica inhibit papain-like protease of severe acute respiratory" exact="syndrome" post="coronavirus. Biol Pharm Bull. (2012) 35:2036â€&quot;42. 10.1248/bpb.b12-0062322971649 163.ZhouYHouYShenJHuangYMartinWChengF. Network-based"/>
 <result pre="Vaccines. (2009) 8:887â€&quot;98. 10.1586/erv.09.4319538115 172.IshiiKHasegawaHNagataNAmiYFukushiSTaguchiFet al.. Neutralizing antibody against severe" exact="acute" post="respiratory syndrome (SARS)-coronavirus spike is highly effective for the"/>
 <result pre="(2009) 8:887â€&quot;98. 10.1586/erv.09.4319538115 172.IshiiKHasegawaHNagataNAmiYFukushiSTaguchiFet al.. Neutralizing antibody against severe acute" exact="respiratory" post="syndrome (SARS)-coronavirus spike is highly effective for the protection"/>
 <result pre="8:887â€&quot;98. 10.1586/erv.09.4319538115 172.IshiiKHasegawaHNagataNAmiYFukushiSTaguchiFet al.. Neutralizing antibody against severe acute respiratory" exact="syndrome" post="(SARS)-coronavirus spike is highly effective for the protection of"/>
 <result pre="the sera of convalescent cases. Virology. (2004) 324:251â€&quot;6. 10.1016/j.virol.2004.04.01715207612 174.Tsunetsugu-YokotaYOhnishiKTakemoriT." exact="Severe" post="acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies"/>
 <result pre="sera of convalescent cases. Virology. (2004) 324:251â€&quot;6. 10.1016/j.virol.2004.04.01715207612 174.Tsunetsugu-YokotaYOhnishiKTakemoriT. Severe" exact="acute" post="respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and"/>
 <result pre="of convalescent cases. Virology. (2004) 324:251â€&quot;6. 10.1016/j.virol.2004.04.01715207612 174.Tsunetsugu-YokotaYOhnishiKTakemoriT. Severe acute" exact="respiratory" post="syndrome (SARS) coronavirus: application of monoclonal antibodies and development"/>
 <result pre="convalescent cases. Virology. (2004) 324:251â€&quot;6. 10.1016/j.virol.2004.04.01715207612 174.Tsunetsugu-YokotaYOhnishiKTakemoriT. Severe acute respiratory" exact="syndrome" post="(SARS) coronavirus: application of monoclonal antibodies and development of"/>
 <result pre="(2020) 369:77â€&quot;81. 10.1126/science.abc193232376603 177.van DoremalenNLambeTSpencerABelij-RammerstorferSPurushothamJNPortJRet al.ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaques. bioRxiv. (2020) 2020.05.13.093195. 10.1101/2020.05.13.093195 178.ZhuF-CLiY-HGuanX-HHouL-HWangW-JLiJ-Xet al.."/>
 <result pre="trial. Lancet. (2020) 6736:1â€&quot;10. 10.1016/S0140-6736(20)31208-332450106 179.BollesMDemingDLongKAgnihothramSWhitmoreAFerrisMet al.. A double-inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccine provides incomplete protection in mice"/>
 <result pre="Lancet. (2020) 6736:1â€&quot;10. 10.1016/S0140-6736(20)31208-332450106 179.BollesMDemingDLongKAgnihothramSWhitmoreAFerrisMet al.. A double-inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccine provides incomplete protection in mice and"/>
 <result pre="(2020) 6736:1â€&quot;10. 10.1016/S0140-6736(20)31208-332450106 179.BollesMDemingDLongKAgnihothramSWhitmoreAFerrisMet al.. A double-inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccine provides incomplete protection in mice and induces"/>
 <result pre="al.. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides" exact="incomplete" post="protection in mice and induces increased eosinophilic proinflammatory pulmonary"/>
 <result pre="coronavirus vaccine provides incomplete protection in mice and induces increased" exact="eosinophilic" post="proinflammatory pulmonary response upon challenge. J Virol. (2011) 85:12201â€&quot;15."/>
 <result pre="provides incomplete protection in mice and induces increased eosinophilic proinflammatory" exact="pulmonary" post="response upon challenge. J Virol. (2011) 85:12201â€&quot;15. 10.1128/jvi.06048-1121937658 180.TsengC"/>
 <result pre="180.TsengC TeSbranaEIwata-YoshikawaNNewmanPCGarronTAtmarRLet al.. Immunization with SARS coronavirus vaccines leads to" exact="pulmonary" post="immunopathology on challenge with the SARS virus. PLoS ONE."/>
 <result pre="(2012) 7:e35421. 10.1371/journal.pone.003542122536382 181.Iwata-YoshikawaNUdaASuzukiTTsunetsugu-YokotaYSatoYMorikawaSet al.Effects of toll-like receptor stimulation on" exact="eosinophilic" post="infiltration in lungs of BALB/c mice immunized with UV-inactivated"/>
 <result pre="infiltration in lungs of BALB/c mice immunized with UV-inactivated severe" exact="acute" post="respiratory syndrome-related coronavirus vaccine. J Virol. (2014) 2:e255â€&quot;6. 10.1128/jvi.00983-14"/>
 <result pre="in lungs of BALB/c mice immunized with UV-inactivated severe acute" exact="respiratory" post="syndrome-related coronavirus vaccine. J Virol. (2014) 2:e255â€&quot;6. 10.1128/jvi.00983-14 182.JiangSHillyerCDuLNeutralizing"/>
 <result pre="189.ContiPRonconiGCaraffaAGallengaCERossRFrydasIet al.. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and" exact="lung inflammation" post="by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol"/>
 <result pre="phase 3, single-arm, prospective study of remestemcel-l, ex vivo culture-expanded" exact="adult" post="human mesenchymal stromal cells for the treatment of pediatric"/>
 <result pre="pediatric patients who failed to respond to steroid treatment for" exact="acute" post="graft-versus-host disease. Biol Blood Marrow Transplant. (2020) 26:845â€&quot;54. 10.1016/j.bbmt.2020.01.01832018062"/>
 <result pre="to respond to steroid treatment for acute graft-versus-host disease. Biol" exact="Blood" post="Marrow Transplant. (2020) 26:845â€&quot;54. 10.1016/j.bbmt.2020.01.01832018062 193.MannonPJ. Remestemcel-L: Human mesenchymal"/>
 <result pre="Remestemcel-L: Human mesenchymal stem cells as an emerging therapy for" exact="Crohn's disease." post="Expert Opin Biol Ther. (2011) 11:1249â€&quot;56. 10.1517/14712598.2011.60296721787241 194.LengZZhuRHouWFengYYangYHanQet al.."/>
 <result pre="NY: ASX announcement (2020). p. 2060â€&quot;2. 196.FangLKarakiulakisGRothM. Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="announcement (2020). p. 2060â€&quot;2. 196.FangLKarakiulakisGRothM. Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir. (2020) 8:e21."/>
</results>
